Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8798000 | 0.89 | DRD2 (0.57) | DRD2DRD4HTR1AHTR2AHTR7 | |
| SCHEMBL13532766 | 0.89 | HTR2A (0.60) | KCNH2DRD2DRD4HTR1AHTR2A | |
| SCHEMBL8797503 | 0.87 | DRD2 (0.61) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL8797552 | 0.84 | DRD2 (0.58) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL8797970 | 0.80 | HTR1A (0.54) | KCNH2DRD2DRD4HTR1AHTR2A | |
| SCHEMBL13532744 | 0.80 | KCNH2 (0.62) | KCNH2DRD2DRD4HTR1AHTR2A | |
| SCHEMBL8797848 | 0.79 | HTR7 (0.53) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL7464063 | 0.78 | POLB (0.45) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL7472167 | 0.78 | POLB (0.45) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL7468722 | 0.78 | POLB (0.45) | DRD2HTR1AHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | claimed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | KCNH2 3934/4885DRD2 242/4885DRD4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.